www.stirlingproducts.net
Stirling Products (ASX:STI) is a manufacturer and marketer of proprietary and/or patented pharmaceutical products and natural health products for its own interests as well as on a contractual basis for third parties. Strategically, Stirling Products is positioned to capitalise on the rapidly changing conditions within the global pharmaceutical and health markets.
The Stirling Products corporate headquarters are in Sydney, Australia and its North American pharmaceutical manufacturing operations are based on Cape Breton, Nova Scotia, Canada.
Stirling operates through three main business units each managed by proven industry specialist managers:
- Pharmaceutical & Healthcare
- Research & Development
- Animal Products
Stirling Products in pre-open pending significant announcements
Stirling Products (ASX: STI) has been granted a trading halt by the ASX, pending several major announcements, with the company's shares placed in pre-open.
Stirling will update the market on:
1. Company strategic review advice;
2. TeleMedCare and Stirling Pharma progress and developments;
3. First exclusive HDA platform licensing for the pulmonary delivery of a major drug; and
4. Proposed UK AIM listing and funding.
The trading halt will last to the earlier of the announcement(s), or trading on Wednesday 15 June.


















